EMA recommends authorization of Teizeild to delay Type 1 diabetes onset

This is the first drug to receive a recommendation for this preventative indication in the European Union

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies

Zydus Lifesciences secures FDA tentative approval for Olaparib tablets

Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers

Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors

Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent

Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors

First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors

Biostar Pharma doses first patient in Phase II/III multiregional trials of utidelone capsule

Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers

The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product

Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability

InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services

Merck’s Welireg receives European approval for two indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union

Cipla receives final approval for the generic version of Somatuline Depot Injection

Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection